Testing Status of AZT/Drug Combinations Transplacental/Neonatal Study M070066
CASRN: AIDSDRUGSNEO
Related: AIDSTHERAPEU
Secondary:
- 134678-17-4 - 3TC (AIDS initiative)
- 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
- 30516-87-1 - AZT transplacental carcinogenesis study
- 154598-52-4 - Efavirenz (EFV)
- 159989-65-8 - Nelfinavir mesylate
- 129618-40-2 - Nevirapine
Short-Term Toxicity
- 28 days (Gavage)
(C20311B)
Completed
- Mice: B6C3F1
Long-Term Carcinogenicity
- 2 years (Gavage)
(C20311B)
Completed
- Mice: B6C3F1 (NCTR)
- Dose: 240 (Dams GD 12-20); 40, 26.6, 13.3 (Neonates PND 1-8) mg/kg/bwt AZT+3TC: 240 AZT, 120 3TC (Dams GD 12-20); 40 AZT, 20 3TC; 26.6 AZT, 13.3 3TC; 13.3 AZT, 6.7 3TC (Neonates PND 1-8) mg/kg/bwt AZT+3TC+NVP: 240 AZT, 120 3TC, 168 NVP (Dams GD 12-20); 40 AZT, 20 3TC, 56 NVP; 26.6 AZT, 13.3 3TC, 37.2 NVP; 13.3 AZT, 6.7 3TC, 18.6 NVP (Neonates PND 1-8) mg/kg/bwt AZT+3TC+NVF: 160 AZT, 80 3TC, 672 NFV (Dams GD 12-20); 40 AZT, 20 3TC, 168 NFV; 26.6 AZT, 13.3 3TC, 112 NFV; 13.3 AZT, 6.7 3TC, 56 NFV (Neonates PND 1-8) mg/kg/bwt AZT+3TC+EFV: 160 AZT, 80 3TC, 160 EFV (Dams GD 12-20); 40 AZT, 20 3TC, 40 EFV; 26.6 AZT, 13.3 3TC, 26.6 EFV; 13.3 AZT, 6.7 3TC, 13.3 EFV (Neonates PND 1-8) mg/kg/bwt.